- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06742801
Onyx™ Liquid Embolic IDE klinisk studie
PELE IDE klinisk studie, Perifer Onyx™ væskeembolisk sikkerhet og effektivitet av Onyx™ LES for embolisering av arteriell blødning i den perifere vaskulaturen
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a pivotal, prospective, multi-center, non-randomized, single arm study. This study will enroll patients with active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by investigator. In this study, peripheral vasculature is defined as outside of the brain and heart.
Approximately 135 subjects will be consented to achieve 119 enrolled at up to 25 sites in the US.
This study will have two visits post-index procedure including hospital discharge visit and 30-day follow-up visit. Reintervention visits will be captured through 30 days post-index procedure.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Liza Marie
- Telefonnummer: 7072172314
- E-post: liza.marie@medtronic.com
Studer Kontakt Backup
- Navn: Janki Shah
- Telefonnummer: 7322662503
- E-post: janki.shah@medtronic.com
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85054
- Rekruttering
- Mayo Clinic
-
Ta kontakt med:
- Debbie Ryan
- Telefonnummer: 480-342-1208
- E-post: ryan.debra29@mayo.edu
-
Hovedetterforsker:
- Sadeer Alzubaidi, MD
-
Ta kontakt med:
- Yahaira Parker
-
-
California
-
Irvine, California, Forente stater, 92627
- Rekruttering
- University of California, Irvine
-
Ta kontakt med:
- Nadine Jaoudeh, MD
- E-post: nadine@hs.uci.edu
-
Ta kontakt med:
- Kimberly Padilla
- E-post: kpadill6@hs.uci.edu
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- University of California Los Angeles
-
Ta kontakt med:
- Renato Escobar
- E-post: raescobar@mednet.ucla.edu
-
Hovedetterforsker:
- Jessica Stewart, MD
-
Palo Alto, California, Forente stater, 94304
- Rekruttering
- Stanford Medical Center
-
Ta kontakt med:
- Andrew Picel, MD
-
Ta kontakt med:
- Abigail Bond
- E-post: abond02@stanford.edu
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- UCHealth University of Colorado Hospital
-
Ta kontakt med:
- Alejandra Aguilar, MPH
- E-post: alejandra.aguilar@cuanschutz.edu
-
Hovedetterforsker:
- Eduardo Bent Robinson, MD
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Rekruttering
- Yale New Haven
-
Ta kontakt med:
- Patricia Fugal
- E-post: patricia.fugal@yale.edu
-
Ta kontakt med:
- Angelo Marino, MD
- E-post: angelo.marino@yale.edu
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago
-
Ta kontakt med:
- Tiana Jackson
- E-post: tiana.jackson@bsd.uchicago.edu
-
Hovedetterforsker:
- Brian Funaki, MD
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- University of Iowa Hospitals and Clinics
-
Hovedetterforsker:
- Michael Hummel, MD
-
Ta kontakt med:
- Victoria Mendoza
- E-post: victoria-mendoza@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Masschusetts General Hospital
-
Ta kontakt med:
- Vincent Wu, MD
- E-post: vwu3@mgh.harvard.edu
-
Ta kontakt med:
- Justin Hill
- E-post: jhill43@mgh.harvard.edu
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68124
- Rekruttering
- CHI Health Creighton University Medical Center-Bergan-Mercy
-
Ta kontakt med:
- Janice Mitchel
- Telefonnummer: 402-619-9402
- E-post: jan.mitchell@commonspirit.org
-
Hovedetterforsker:
- Patrick Harty
-
-
New Jersey
-
Newark, New Jersey, Forente stater, 07103
- Rekruttering
- Rutgers New Jersey Medical School
-
Hovedetterforsker:
- Abhishek Kumar, MD
-
Ta kontakt med:
- Saharsh Patel
- E-post: ssp186@gsbs.rutgers.edu
-
-
New York
-
Albany, New York, Forente stater, 12208
- Rekruttering
- Albany Medical Center
-
Ta kontakt med:
- Nancy Spencer, NP
- E-post: spencen@amc.edu
-
Ta kontakt med:
- Gary Siskin, MD
- E-post: sisking@amc.edu
-
New York, New York, Forente stater, 10029
- Rekruttering
- The Mount Sinai
-
Ta kontakt med:
- Rajesh Patel, MD
- E-post: rajesh.patel@mountsinai.org
-
Ta kontakt med:
- Aaron Greenberg
- E-post: aaron.greenberg@mountsinai.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- Rekruttering
- University of North Carolina at Chapel Hill
-
Hovedetterforsker:
- Nima Kokabi, MD
-
Ta kontakt med:
- Adriana Delgado
- E-post: adriana_delgado@med.unc.edu
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- Rekruttering
- University Hospitals Cleveland Medical Center
-
Ta kontakt med:
- Lauren Hahn
- E-post: lauren.hahn@uhhospitals.org
-
Hovedetterforsker:
- Salim Abboud, MD
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The Ohio State University
-
Ta kontakt med:
- Mina Makary, MD
-
Ta kontakt med:
- Gage Spears
- E-post: gage.spears@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15237
- Rekruttering
- University of Pittsburgh Medical Center
-
Hovedetterforsker:
- Paula Novelli, MD
-
Ta kontakt med:
- Suzanne Burdin
- E-post: burdins@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37212
- Rekruttering
- Vanderbilt University Medical Center
-
Ta kontakt med:
- Celia Nunez
- Telefonnummer: 615-322-4559
- E-post: celia.m.nunez@vumc.org
-
Hovedetterforsker:
- Anthony Borgmann, MD
-
-
Texas
-
Dallas, Texas, Forente stater, 75235
- Rekruttering
- Univ Of Texas Southwestern
-
Hovedetterforsker:
- Sanjeeva Kalva, MD
-
Ta kontakt med:
- Camille Harry
- Telefonnummer: 214-648-8986
- E-post: camille.harry@utsouthwestern.edu
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- The University of Texas Health Science Center at Houston
-
Ta kontakt med:
- Praneeth Nadimpalli
- E-post: praneeth.v.nadimpalli@uth.tmc.edu
-
Ta kontakt med:
- Lauren McGuire, RN
- E-post: lauren.c.mcguire@uth.tmc.edu
-
Hovedetterforsker:
- Rodrick Zvavanjanja, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patient is ≥ 22 years old.
-
Active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator.
In this study, peripheral vasculature is defined as outside the brain and heart.
-
Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.
-
Life expectancy of >30 days, in the opinion of the investigator at the time of enrollment.
-
Target treatment area is free from prior embolization treatment.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Symptoms of active infection.
- Patient is known to be participating in the study of an investigational drug, biologic, or device.
- Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.
- Known allergy to components of Onyx™.
- Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.
- More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Treatment with Onyx LES
Device; embolization with liquid embolic |
The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Freedom from Arterial Hemorrhage
Tidsramme: Through 30 days post-index procedure
|
Freedom from arterial hemorrhage in all target location(s) after treatment with Onyx™ LES at the index procedure without re-embolization or any other intervention at the target location(s) due to persistent or recurrent hemorrhage through 30 days. Freedom from arterial hemorrhage where an arterial hemorrhage event is defined as a type 3 or greater BARC bleeding criteria as assessed by the Clinical Events Committee (CEC) through 30 days. |
Through 30 days post-index procedure
|
|
Freedom from System-related Major Adverse Events (MAE)
Tidsramme: Through 30 days post-index procedure
|
The primary safety endpoint is defined as freedom from system-related Major Adverse Events (MAE) through 30 days after the point of enrollment as assessed by the CEC. |
Through 30 days post-index procedure
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Procedural Success
Tidsramme: At the completion of the index procedure
|
successful delivery and deployment of Onyx™ to the target location without non-target embolization or Onyx™ cast migration and the successful removal of the delivery system at the completion of the index procedure. |
At the completion of the index procedure
|
|
Technical Success
Tidsramme: At the completion of the index procedure
|
Technical Success is defined as absence of angiographic signs of bleeding after Onyx ™ embolization at each target location based on core lab assessment. |
At the completion of the index procedure
|
|
Reintervention
Tidsramme: Through 30 days post-index procedure
|
Reintervention is defined as the number of additional procedures needed to treat the target location(s) embolized with Onyx™ through 30 days following the index procedure. |
Through 30 days post-index procedure
|
|
Transfusions
Tidsramme: Through 30 days post-index procedure
|
Transfusions defined as the number of blood transfusions required post-index procedure through 30 days will use blood transfusions starting after the removal of the delivery system. The number of blood units used for each transfusion will also be collected. |
Through 30 days post-index procedure
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Ancillary Endpoint
Tidsramme: Through index procedure
|
Duration of the index procedure |
Through index procedure
|
|
Ancillary Endpoint
Tidsramme: Through 30 days post-index procedure
|
Length of hospitalization, post-index procedure |
Through 30 days post-index procedure
|
|
Ancillary Endpoint
Tidsramme: Through 30 days post-index procedure
|
Tabulate adjunctive use of other types of embolic agents to treat target locations at index procedure and reinterventions |
Through 30 days post-index procedure
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Osman Ahmed, MD, University of Chicago
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- MDT21044
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .